engleski

Neuroprotective pharmacotherapy of traumatic brain injury

Despite numerous preclinical and clinical research of pathophysiology and therapy of traumatic brain injury (TBI) for at least three decades, it remains the most significant cause of mortality and long-term disability in persons younger than 45 years worldwide. Today's standard therapy of TBI patients is supportive and symptomatic. It includes different and important therapeutic approaches such as the maintenance of general haemodynamic stability and respiration, the management of cerebral perfusion pressure, optimization of brain tissue oxygenation and the control of increased intracranial pressure to restrain the primary insult and minimize secondary injury. To date, an effective neuroprotective agent proven to improve outcomes in TBI patients has not been verified. One possible reason could be the complex and heterogenous pathobiology of TBI that includes different cellular, molecular, biochemical and metabolic events that lead to progressive tissue damage and associated cell death. Because the primary injury is irreversible and cannot be pharmacologically affected, novel pharmacological options have been focused on the secondary injury. Unlike past preclinical and clinical therapeutic investigations that were most frequently focused on the drugs acting on particular steps in the cascade events included in TBI, recently in this field, the point of interest is on multifunctional drugs that target different harmful pathomechanisms. In this talk an overview of the current knowledge on neuroprotective strategies for TBI will be showed.

neuroprotection ; pharmacotherapy ; traumatic brain injury

nije evidentirano